Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial

Scand J Rheumatol. 2011 May;40(3):232-3. doi: 10.3109/03009742.2010.517548. Epub 2010 Nov 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Biomarkers / analysis
  • C-Reactive Protein / analysis*
  • Endpoint Determination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Biomarkers
  • C-Reactive Protein
  • Adalimumab